Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
In Patients with Heart Attacks, CYPHER(R) Sirolimus-Eluting Coronary Stent Results Sustained out to Four Years Compared to Bare Metal Stents May 19, 2009 |
12.2 KB |
|
|
BARCELONA, Spain, May 19, 2009 (BUSINESS WIRE) -- Four-year results of a large, multi-center clinical trial show that earlier results favoring the CYPHER(R) Sirolimus-eluting Coronary Stent over bare metal stents (BMS) in patients with acute myocardial infarction (heart attack) were maintained in long-term follow-up.... |
|||
|
NEVO(TM) Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus(R) Liberte(R) Stent in Pivotal Clinical Trial May 19, 2009 |
19.0 KB |
|
|
BARCELONA, Spain, May 19, 2009 (BUSINESS WIRE) -- At six months, the NEVO(TM) Sirolimus-eluting Coronary Stent, incorporating RES Technology(TM), was superior to the Taxus(R) Liberte(R) Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results relea... |
|||
|
FDA Grants Approval for Use of RISPERDAL® CONSTA® as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder May 18, 2009 |
22.5 KB |
|
|
Titusville, N.J., May 18, 2009 - Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment as both monotherapy... |
|||
|
Benefits of Catheter Ablation with the NAVISTAR(R) THERMOCOOL(R) Catheter Sustained for One Year in the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation May 14, 2009 |
16.5 KB |
|
|
BOSTON, May 14, 2009 (BUSINESS WIRE) -- In final, one-year results of a multicenter randomized clinical study, catheter ablation demonstrated significantly better outcomes compared to anti-arrhythmic drug (AAD) therapy for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. Atrial f... |
|||
|
Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients with Epoetin Alfa Associated with Lower Drug Cost than Darbepoetin Alfa May 13, 2009 |
36.0 KB |
|
|
HORSHAM, Pa., May 13, 2009 -- Data from a study of managed-care cancer patients receiving chemotherapy and newly treated with erythropoiesis-stimulating agents (ESAs) found that the cumulative ESA cost with Epoetin alfa (EPO) was 29 percent lower than treatment with darbepoetin alfa (DARB). The analysis, published in the Spring issue of t... |
|||
|
Biosense Webster to Showcase Advanced Ablation Technologies for Electrophysiologists at HRS 2009 May 13, 2009 |
13.8 KB |
|
|
DIAMOND BAR, Calif., May 13, 2009 (BUSINESS WIRE) -- Biosense Webster, Inc., the worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase its portfolio of advanced technologies treating abnormal heart rhythms during the Heart Rhythm Society's (HRS) 30th Annual Scientific Sessions. ... |
|||
|
Johnson & Johnson to Participate in Deutsche Bank 34th Annual Health Care Conference May 13, 2009 |
5.7 KB |
|
|
NEW BRUNSWICK, N.J., May 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19th, at the InterContinental Boston hotel in Boston. Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group for Johnson & Johnson, will represent... |
|||
|
Johnson & Johnson to Host Analyst Conference Call To Review Six-Month Trial Results From NEVO RES I May 12, 2009 |
6.8 KB |
|
|
NEW BRUNSWICK, N.J., May 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at noon (Eastern Time) on Tuesday, May 19, 2009 to review the primary data from NEVO RES I, the pivotal European trial of the NEVO(TM) Sirolimus-eluting Coronary Stent. NEVO(TM) is the... |
|||
|
Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009 May 7, 2009 |
8.3 KB |
|
|
NEW BRUNSWICK, N.J., May 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- In letters to Senate Special Committee on Aging Chairman Herb Kohl (D-WI) and Senate Finance Committee Ranking Member Charles Grassley (R-IA), Johnson & Johnson today announced its support for the Physician Payments Sunshine Act of 2009 (S. 301). The company also com... |
|||
|
Cellsearch® System to be Offered at Florida Cancer Specialists May 7, 2009 |
7.7 KB |
|
|
RARITAN, N.J., (May 7, 2009) - Veridex, LLC announced today that the CellSearch® System to measure circulating tumor cells (CTCs) will be offered at Florida Cancer Specialists (FCS), the largest privately-owned oncology and hematology practice in Florida. Veridex's CellSearch® test is used to predict survival... |
|||
|
Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting May 7, 2009 |
10.3 KB |
|
|
San Diego, CA - May 7, 2009 - Chronic pain is a significant medical challenge in the United States, and chronic low back pain is the most common cause of disability in developed countries. An estimated 100 million Americans suffer from chronic pain each year. If left undertreated, chronic pain can impair an individual's ability to carry out dail... |
|||
|
Johnson & Johnson to Participate in Bank of America and Merrill Lynch 2009 Health Care Conference May 5, 2009 |
5.7 KB |
|
|
NEW BRUNSWICK, N.J., May 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12th, at The Palace Hotel, New York, N.Y. Donald M. Casey, Jr., Worldwide Chairman, Comprehensive Care Group for Johnson & Johnson, wi... |
|||
|
Simponi™ (Golimumab) Receives FDA Approval As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis Apr 24, 2009 |
17.9 KB |
|
|
Horsham, PA (April 24, 2009) -- Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI™ (golimumab) for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. SIMPONI is the first patient-a... |
|||
|
Johnson & Johnson Announces Dividend Increase of 6.5% Apr 23, 2009 |
5.8 KB |
|
|
NEW BRUNSWICK, N.J., April 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.5% increase in the quarterly dividend rate, from $0.46 per share to $0.49 per share. The increase was announced this morning at the Annual Meeting of Shareholders in New Br... |
|||
|
Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured In 15 Presentations At SAGES Apr 22, 2009 |
10.4 KB |
|
|
CINCINNATI - April 22, 2009 - Ethicon Endo-Surgery today announced the company's novel, investigational*devices, including its NOTES Toolbox™, are featured in 15 studies being presented at the 2009 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Meeting. Setting the stage for ... |
|||
|
FDA Grants Ethicon Endo-Surgery Approval of its IDE Application to Commence Study of Notes Toolbox™ Apr 22, 2009 |
7.5 KB |
|
|
CINCINNATI - April 22, 2009 - Ethicon Endo-Surgery today announced that the U.S. Food and Drug Administration (FDA) granted approval of the company's Investigational Device Exemption (IDE) application to conduct the first study of devices designed for use in natural orifice translumenal endoscopic surgery (NOTES). The company is the first... |
|||
|
Virco Lab, Inc. enters into Collaboration with SmartGene, Inc. enhancing HIV resistance test services for laboratories and physicians Apr 21, 2009 |
10.2 KB |
|
|
April 20, 2009 Virco Lab, Inc. a leader in HIV resistance testing services, is pleased to announce a US collaboration with SmartGene, Inc. a provider of novel services for the management and analysis of genetic data to provide laboratories and physicians with greater insight into HIV drug resistance and to transfer the ordering, viewing a... |
|||
|
Johnson & Johnson to Webcast Annual Meeting of Shareholders Apr 16, 2009 |
6.2 KB |
|
|
New Brunswick, NJ (April 16, 2009) - Johnson & Johnson will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, from the Hyatt Regency Hotel in New Brunswick, N.J. Investors and other interested parties may access the meeting by visiting the Company's website at www.j... |
|||
|
Johnson & Johnson Reports 2009 First-Quarter Results Apr 14, 2009 |
25.0 KB |
|
|
NEW BRUNSWICK, N.J., April 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.0 billion for the first quarter of 2009, a decrease of 7.2% as compared to the first quarter of 2008. Operational results declined 1.2% and the negative impact of currency was 6.0%. Domestic sales declined... |
|||
|
Health Canada Approves Simponi™ (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis Apr 13, 2009 |
16.2 KB |
|
|
HORSHAM, Pa. and KENILWORTH, N.J., April 13, 2009 - Centocor Ortho Biotech, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that Health Canada has granted approval of SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic ar... |
|||
= add release to Briefcase
